Intelicare Holdings Limited Overview
InteliCare is a Perth-based software-as-a-service company. It commercialises a proprietary, AI-driven Internet-of-Things care platform for Australian residential aged care, retirement living, disability and health providers. The platform combines ambient sensors, vital-sign and bed-occupancy monitoring, falls detection, real-time location tracking, staff duress and, since 2026, a proprietary nurse call layer, all in one clinical dashboard. Its purpose is to improve resident safety, reduce manual welfare checks and support compliance under Australia's new aged care regulatory regime. After six years of pilots, sub-scale revenue and repeated equity raisings, the company reached its first commercial inflection in FY2026. It signed a five-year, roughly A$8.8 million Master Subscription Agreement with mecwacare covering 22 facilities and about 1,600 beds. It expanded its Hardi Aged Care contract, entered retirement living through Warrigal, more than doubled sales revenue, and recorded its first positive operating cash flow quarter since listing. It remains loss-making, highly concentrated by customer and heavily dilutive.
Company's own description
In its FY2026 Directors' Report, InteliCare describes its principal activities as three items: production of a predictive analytics solution for care providers in aged care, disability and healthcare; sales and marketing; and research and development. ASX announcements in 2026 describe it as an Australian SaaS technology company commercialising its AI-driven InteliCare platform across the aged care, disability and health sectors. The longer boilerplate in its releases says it uses smart sensors and AI on a proprietary IoT platform to help people stay in their own homes for longer, while helping providers deliver better and more efficient care.
The FY2026 report describes the year as a transition from validating pilots to deploying at scale. The company focused on converting pilots into long-term contracts, carrying out deployments with leading aged care providers, building recurring SaaS revenue and improving the platform for larger, cheaper rollouts.
Independent characterisation
InteliCare is in practice a hardware-led, SaaS-tailed solution vendor to institutional aged care operators. Its value proposition has three parts:
-
Clinical safety. It detects falls, bed exits and changes in vital signs or behaviour patterns, and raises alerts.
-
Workforce productivity. It replaces manual overnight welfare rounds. In the mecwacare Trescowthick pilot, residents needing three-hourly overnight checks fell from 55 to 4.
-
Compliance and governance. It automates falls reporting, keeps audit trails and analyses alarm response times, which supports alignment with the new Aged Care Act and the strengthened Aged Care Quality Standards.
The company began in 2020 with a home-monitoring and B2C/B2B home care model. Its products then were InteliCare Home and InteliLiving, funded through Home Care Packages and NDIS plans. Since about 2022–2023 it has pivoted firmly toward residential aged care. The 2026 launch of a proprietary nurse call solution marks a further move. InteliCare is no longer only an analytics overlay. It is starting to compete for, or displace parts of, the core clinical communications layer of an aged care facility. That brings it into direct competition with established nurse call vendors.
Revenue model
| Revenue stream | Description | Recognition | FY2025 (AUD) | FY2026 (AUD) | FY2026 mix |
|---|---|---|---|---|---|
| Hardware sales (incl. bundled implementation) | Sensors, hubs, gateways, nurse call hardware, plus implementation services bundled where not distinct | Point in time (on delivery) | 847,025 | 1,845,029 | 90.4% |
| Subscription (SaaS) | Platform subscription fees per bed, site or residence | Over time | 109,715 | 196,799 | 9.6% |
| Professional services | Referenced in mecwacare contract terms; not separately reported | — | — | — | — |
| Total sales revenue | — | — | 956,740 | 2,041,828 | 100% |
Source: FY2026 Financial Report, Note 5: Other income outside sales revenue consists of the R&D tax incentive refund (A$610,680 in FY2026; A$619,528 in FY2025) and interest income. This income is material: in FY2026 it equalled about 30% of sales revenue.
Commercial contracts are structured as multi-year Master Subscription Agreements. Each facility has its own order form, with up-front hardware and implementation fees followed by recurring SaaS. In the June 2026 quarter, hardware fees made up about 69% of cash receipts (Kalkine summary of the June 2026 Quarter Update). The share of recurring revenue is still small, but it is growing: SaaS revenue rose 79.4% year on year in FY2026.
Value chain position, customer types and end-markets
| End-market | Status | Named customers / counterparties |
|---|---|---|
| Residential aged care (RAC) | Core market; most revenue in FY2025–FY2026 | mecwacare (VIC), Hardi Aged Care (NSW) |
| Retirement living | Entered FY2026 (first commercial deployment) | Warrigal Care (NSW/ACT) |
| Regional / public health | Ongoing subscription | WA Country Health Service (WACHS), Koolberrin Lodge, Narembeen |
| Home care / disability | Original market (2020–2022); now secondary | Historical: WA Department of Communities, Swan Care, Echo Community Services, Like Our Own |
| Hospital / remote patient monitoring | Pilot stage | Peter MacCallum Cancer Centre pilot (concluded early 2024) |
InteliCare designs the software, analytics and AI layer and specifies the sensor and hardware stack. Hardware is purchased and resold; hardware expense was A$882,227 in FY2026. Manufacturing arrangements are not publicly disclosed. The company handles implementation itself.
All FY2026 external revenue came from sales to Australian aged care providers (FY2026 Financial Report, Note 4).
Strategy
Stated strategy (themes from the FY2026 annual results and the 21 April 2026 investor presentation)
The company's stated themes, paraphrased:
-
Convert pilots into long-term contracts. Trescowthick became the mecwacare MSA; the WACHS proof of concept became an ongoing subscription.
-
Scale deployments with anchor customers. Complete the mecwacare (22 facilities), Hardi (6 facilities plus nurse call) and Warrigal rollouts.
-
Grow recurring SaaS revenue as installed beds come online.
-
Improve deployment economics. Zero-touch sensor setup, LiDAR-assisted installation and automated calibration.
-
Expand across the continuum of care. Residential aged care, retirement living, and potentially home care and new service models (named as a joint innovation area with mecwacare).
-
Regulatory alignment. Position the platform as supporting compliance with the new Aged Care Act and the strengthened Aged Care Quality Standards.
Management described the company as being at a "commercial inflexion point" in the June 2026 quarter update.
Strategic initiatives in the last 24 months
| Initiative | Date | Detail | Status |
|---|---|---|---|
| mecwacare five-year strategic partnership | Mar 2026 | MSA plus collaboration on innovation, data-driven care insights, knowledge exchange and at-home care applications | Rolling out (4 sites live; 10 targeted by Dec 2026) |
| Proprietary nurse call launch | FY2026 | Built from mecwacare's preference for a single platform; can replace legacy nurse call functions | Live at 2 Hardi sites; installing at 2 more |
| Retirement living entry | Apr 2026 | Warrigal: 65 villas; pathway to 10 villages | Implementation |
| Hardi expansion | Jul 2026 | +84 beds at Blacktown; nurse call across 6 sites | Underway |
| Product automation program | FY2026 | Zero-touch sensors, LiDAR installer app, GenAI event summaries | Delivered |
| Capital structure simplification | Sep 2025 | Convertible note facility terminated | Completed |
| Leadership upgrade | Mar 2026 | CEO with multinational health technology background | Completed |
Medium-term targets and guidance
| Target | Horizon | Source |
|---|---|---|
| 10 mecwacare sites live | End of calendar 2026 | June 2026 Quarter Update; FY2026 Directors' Report |
| Remaining 2 Hardi facilities deployed | End of calendar 2026 | FY2026 Directors' Report |
| mecwacare full rollout (22 facilities) | FY2026–FY2028 | FY2026 Directors' Report |
| 700 / 2,000 / 4,000 contracted revenue-generating beds | 30 Jun 2027 / 2028 / 2029 | CEO performance rights hurdles (FY2026 Remuneration Report) |
| Revenue, EBITDA or profit guidance | None issued | — |
ESG or sustainability commitments: none disclosed. Formal cost reduction programs: none disclosed, although FY2023 reporting highlighted reductions in monthly cash burn.
Products & Services
All products sit within the single reported segment. They are listed individually below.
Sources: FY2026 Directors' Report (Technology and product development); Morningstar profile; startupnews.com.au (May 2020); The Weekly Source (May 2020); StockWireX (March 2026); ASX Hardi announcement (28 July 2026); Stockhead (2022).
Flagship offering. The integrated "analytics, IoT, alerts, sensors and nurse call" bundle being deployed across mecwacare under the five-year MSA.
Pricing disclosure. Per-bed or per-site pricing is not publicly disclosed. Contract-level economics are disclosed for three customers:
Derived aggregate disclosed TCV: about A$12.3M.
Product Portfolio
| # | Product / module | Description and capabilities | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|---|
| 1 | InteliCare Platform (core) | Proprietary AI and predictive analytics IoT platform. It ingests sensor, vital-sign, bed, location and alarm data and issues alerts and insights | RAC, retirement living, disability, health | Commercial since 2020; enhanced continuously through FY2026 | Hardware plus implementation plus recurring SaaS per facility order form |
| 2 | InteliLiving | Original core app for families and carers giving a real-time view of wellbeing in independent living; listed on Microsoft Azure Marketplace | Seniors and people with disability at home; home care providers | 2,020 | Monthly subscription, fundable via HCP or NDIS (2020 model) |
| 3 | InteliCare Home | Smart-sensor package that learns occupants' normal behaviour without cameras and alerts carers to anomalies | Consumers / home care | 2,020 | Hardware plus subscription |
| 4 | InteliCare Pro | Multi-client interface for residential aged care operators | RAC operators | 2,020 | — |
| 5 | InteliCare Hub | Gateway or hub device that connects the sensors | All segments | — | Hardware sale |
| 6 | Smart sensors | Ambient motion and environmental sensors, bed occupancy sensors, vital-sign sensing; auto-detection and zero-touch setup added in FY2026 | All segments | Ongoing; zero-touch configuration FY2026 | Hardware sale |
| 7 | Duress pendants (optional) | Wearable personal alarms | Residents and staff | — | Hardware sale |
| 8 | Falls detection and end-to-end falls management | Falls detection (100% accuracy, no missed or false falls during the Trescowthick evaluation), event classification, reassignment, manual event creation, automated falls reporting | RAC | Enhanced FY2026 | Included in SaaS |
| 9 | Vital signs and bed occupancy monitoring | Real-time overnight monitoring that replaces three-hourly welfare checks | RAC | FY2025–FY2026 | Included in SaaS |
| 10 | InteliCare Nurse Call (proprietary) | Nurse call display and management; can integrate with or replace legacy nurse call functions. Developed at mecwacare's request for a single unified platform | RAC operators | 2026 (live at Hardi Manly Vale and Blacktown; installing at Wyoming and Seven Hills) | Separate fees (part of the A$371k Hardi uplift) |
| 11 | Staff CONNECT app | Mobile app for care staff: real-time alarm visibility, location search for residents, staff and equipment, proximity-based alarm closure | Care staff | FY2026 | Included in SaaS |
| 12 | Facility Manager Dashboard | Single real-time view of resident and facility data combining falls, vitals, bed exit, duress and nurse call | Facility managers | FY2026 | Included in SaaS |
| 13 | Alarm analytics | Call volumes and response times by shift and across 24-hour cycles | Management, quality and compliance | FY2026 | Included in SaaS |
| 14 | Real-time location system (RTLS) | Live location tracking of equipment, staff and residents; asset management | RAC | Improved FY2026 | Included in SaaS |
| 15 | Annunciator application | Configurable alarm annunciation display | RAC | FY2026 | Included in SaaS |
| 16 | LiDAR installer application | Uses LiDAR to automate spatial data collection and optimise sensor placement, lowering deployment cost | Internal and installers | FY2026 | Internal tool |
| 17 | Generative AI event summaries | Better event-confidence categorisation feeding GenAI analysis and event summaries | Clinical and management staff | FY2026 | Included in SaaS |
| 18 | Wearables integration | Integration with a wide range of consumer smart-health wearables | Home care | FY2022 | — |
| 19 | Implementation and professional services | Site survey, installation, configuration, integration with existing nurse call and care management systems | All contracted customers | Ongoing | Implementation fees and professional services under MSAs |
“—” = not publicly disclosed.
| Contract | Term | Estimated TCV (AUD) | Composition |
|---|---|---|---|
mecwacare (MECWA Limited) | 5 years (signed Mar 2026; rollout FY2026–FY2028) | ~8,800,000 | Hardware, implementation, recurring SaaS, professional services across 22 facilities (~1,600 residents) |
Hardi Aged Care (initial) | 3 years (from 2024) | ~2,900,000 | ~A$1.7M hardware and implementation; ~A$400k per year SaaS at full deployment across 6 facilities |
Hardi expansion | Added Jul 2026 | ~371,000 (initial) | Blacktown +84 beds; nurse call at Blacktown and Manly Vale; four more nurse call sites to be invoiced |
Warrigal Care | 3 years plus annual renewals | ~200,000 | Hardware, implementation, SaaS for 65 villas; about A$152k described as annual SaaS subscription payments in the June quarter update |
WACHS (Koolberrin Lodge) | 2 years plus three 1-year options | — | Ongoing subscription after a two-year proof of concept |
“—” = not publicly disclosed.
Financial Narrative
Income statement (five years)
Sources: FY2026 Remuneration Report five-year summary (sales revenue, EBITDA, loss, basic EPS); FY2026 Note 9 (diluted EPS equals basic because the company is loss-making). FY2022 growth of 18% is from the FY2022 Annual Report letter. Other growth and margin figures are derived. Four-year sales revenue CAGR FY2022–FY2026: about 47.6% (derived).
Detailed P&L (two years)
Source: FY2026 Statement of Profit or Loss. The company does not report gross profit or operating income; the derived lines are this analyst's calculations. EBIT equals loss before tax plus finance costs, and includes R&D grant income.
Commentary.
The defining inflection of FY2026 is that sales revenue more than doubled while cash operating costs (excluding hardware cost of goods and share-based payments) stayed broadly flat. Staff costs fell 7.1%. Consultant and administrative costs rose 28.6% and 12.8% respectively. The derived gross margin narrowed slightly, from 59.7% to 56.8%, as the mix shifted toward hardware-heavy initial deployments.
The underlying EBITDA loss improved by A$220,727. The headline net loss improved by only A$146,447 (6.5%), held back by two items. First, share-based payment expense rose about 3.7 times as the board and new CEO received performance rights. Second, finance costs rose about 80% because of the 15% interest rate on the R&D-secured loan.
The long-run trend shows operating discipline. The EBITDA loss has more than halved from A$3.78M in FY2022 to A$1.84M in FY2026, while sales revenue rose 4.75 times. FY2023 and FY2024, however, show the danger in this business model: revenue fell while the company waited for pilots to convert into contracts.
Other income, almost entirely the refundable R&D tax offset, is a structural support to the P&L. It has fallen gradually: about A$1.09M for the FY2022 claim, A$926k for FY2023, A$620k for FY2024 and A$611k for FY2025.
Balance sheet
Sources: FY2026 Financial Report (balance sheet, statement of changes in equity, Note 10 financing reconciliation). FY2024 figures are opening balances at 1 July 2024. FY2022–FY2023 balance sheet data were not available in the reviewed sources and are therefore not shown.
Short-term vs long-term debt: all borrowings are current. The R&D offset advance (A$461,538) carries 15% interest. Insurance premium funding is A$36,102. No long-term debt. No goodwill or capitalised intangibles; all development is expensed. The Appendix 4E reports NTA per share of 0.17 cents for the current period and (0.17) for the prior period.
Commentary. The balance sheet was repaired in FY2026. Net liabilities of A$833k became net assets of A$1.23M, and cash rose more than six-fold to A$2.73M. This was driven by about A$4.05M of gross equity raised (September 2025 and May 2026 placements), not by internally generated cash. Accumulated losses since inception now stand at A$20.99M against A$18.97M of paid-in capital. Contract liabilities of A$682k (payments received in advance) are a modest positive sign of customer prepayment. The company has no capitalised development costs, which makes its asset base conservative.
Cash flow
Source: FY2026 Statement of Cash Flows. FCF = operating cash flow minus capex (derived).
Quarterly inflection. In the June 2026 quarter, customer receipts were A$1.806M out of a full-year total of A$2.121M, which implies only about A$315k in the first nine months. Net operating cash flow was +A$384k, the first positive quarter since the 2020 listing. Roughly A$1.5M of receipts came from mecwacare, and hardware made up about 69% of receipts. The company drew its A$400k R&D facility in full and ended the quarter with A$2.73M in cash (June 2026 Appendix 4C; Kalkine summaries).
Assessment. The positive quarter was driven by up-front hardware billings on a burst of mecwacare deployments, not by recurring revenue covering fixed costs. Sustaining positive cash flow depends on keeping deployment pace up (mecwacare targets 10 live sites by December 2026) until SaaS fees build up enough to cover the cost base, which is roughly A$3.8M a year in supplier and employee payments.
Ratios
All ratios are this analyst's calculations from FY2026 Financial Report data. For this issuer, standard profitability ratios are not meaningful (n/m).
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Revenue by Segment (AUD) and Segment Margins & Growth (%)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Segment sales revenue (AUD) | 280,292 | 956,740 | 2,041,828 |
Segment result: loss before tax (AUD) | -2,259,315 | -2,244,263 | -2,097,816 |
Segment EBITDA (AUD) | -2,094,265 | -2,065,657 | -1,844,930 |
YoY sales revenue growth (%) | -30.7 | 241.3 | 113.4 |
Contribution to total revenue (%) | 100 | 100 | 100 |
EBITDA margin (%) | -747.2 | -215.9 | -90.4 |
Revenue type
| Revenue type | FY2025 | FY2026 |
|---|---|---|
Hardware sales (AUD) | 847,025 | 1,845,029 |
Subscription / SaaS (AUD) | 109,715 | 196,799 |
Total sales revenue (AUD) | 956,740 | 2,041,828 |
SaaS share of sales revenue (%) | 11.5 | 9.6 |
Revenue by Segment (AUD)
| Metric | H1 FY2026 | H2 FY2026 |
|---|---|---|
Sales revenue (AUD) | 489,707 | 1,552,121 |
Income Statement (AUD) and Margin Analysis (%)
| Metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Sales revenue (AUD) | 429,845 | 404,345 | 280,292 | 956,740 | 2,041,828 |
Sales revenue growth (%) | 18 | -5.9 | -30.7 | 241.3 | 113.4 |
EBITDA (AUD) | -3,775,617 | -2,892,387 | -2,094,265 | -2,065,657 | -1,844,930 |
Net loss after tax (AUD) | -3,932,938 | -2,998,160 | -2,259,315 | -2,244,263 | -2,097,816 |
Basic EPS (AUD cents) | -3.80 | -1.80 | -1.00 | -0.49 | -0.35 |
Diluted EPS (AUD cents) | -3.80 | -1.80 | -1.00 | -0.49 | -0.35 |
Dividends per share (AUD cents) | 0 | 0 | 0 | 0 | 0 |
EBITDA margin (%) | -878.4 | -715.3 | -747.2 | -215.9 | -90.4 |
Net margin (%) | -915.0 | -741.5 | -806.1 | -234.6 | -102.7 |
Income Statement (AUD) and Margin Analysis (%) (FY2025–FY2026)
| Line item | FY2025 | FY2026 |
|---|---|---|
Sales revenue (AUD) | 956,740 | 2,041,828 |
Other income incl. R&D grants and interest (AUD) | 627,374 | 619,355 |
Total revenue and income (AUD) | 1,584,114 | 2,661,183 |
Hardware expense (AUD) | -385,173 | -882,227 |
Derived gross profit: sales minus hardware expense (AUD) | 571,567 | 1,159,601 |
Derived gross margin (%) | 59.7 | 56.8 |
Development expense (AUD) | -310,530 | -297,791 |
Marketing and advertising (AUD) | -7,622 | -34,042 |
Staff expense (AUD) | -1,660,699 | -1,543,224 |
Consultants (AUD) | -397,077 | -510,535 |
Administrative (AUD) | -797,919 | -900,344 |
Share-based payments (AUD) | -90,751 | -337,950 |
Depreciation and amortisation (AUD) | -94,377 | -101,589 |
Derived operating result / EBIT (AUD) | -2,160,034 | -1,946,519 |
Finance costs (AUD) | -84,229 | -151,297 |
Loss before tax (AUD) | -2,244,263 | -2,097,816 |
Income tax (AUD) | 0 | 0 |
Balance Sheet (AUD)
| Metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Cash and cash equivalents (AUD) | 834,198 | 410,532 | 2,727,755 |
Borrowings, all current (AUD) | 591,759 | 615,236 | 497,640 |
Lease liabilities (AUD) | 20,630 | 101,382 | 27,182 |
Total debt incl. leases (AUD) | 612,389 | 716,618 | 524,822 |
Net debt; negative means net cash (AUD) | -221,809 | 306,086 | -2,202,933 |
Total equity (AUD) | -168,321 | -833,170 | 1,229,900 |
Issued capital (AUD) | 14,628,116 | 15,864,779 | 18,968,387 |
Accumulated losses (AUD) | -16,815,150 | -19,059,413 | -20,987,829 |
Balance Sheet (AUD) and Per-Share Data
| Metric (FY2026 report only) | FY2025 | FY2026 |
|---|---|---|
Total assets (AUD) | 1,021,881 | 3,336,487 |
Total current assets (AUD) | 835,967 | 3,241,855 |
Trade and other receivables (AUD) | 137,322 | 290,781 |
Inventories (AUD) | 207,308 | 147,554 |
Total current liabilities (AUD) | 1,784,974 | 2,061,392 |
Contract liabilities / deferred revenue (AUD) | 579,537 | 681,697 |
Total liabilities (AUD) | 1,855,051 | 2,106,587 |
Working capital (AUD) | -949,007 | 1,180,463 |
Goodwill and intangibles (AUD) | 0 | 0 |
Net tangible assets per share (AUD cents) | -0.17 | 0.17 |
Cash Flow (AUD)
| Metric | FY2025 | FY2026 |
|---|---|---|
Receipts from customers (AUD) | 989,495 | 2,121,281 |
Payments to suppliers and employees (AUD) | -3,233,719 | -3,838,770 |
Government R&D grants received (AUD) | 619,528 | 610,680 |
Net interest paid (AUD) | -42,197 | -77,327 |
Operating cash flow (AUD) | -1,666,893 | -1,184,136 |
Capex: plant and equipment (AUD) | -7,094 | -3,814 |
Free cash flow (AUD) | -1,673,987 | -1,187,950 |
Net proceeds from share issues incl. options (AUD) | 1,453,971 | 3,816,640 |
Net borrowings (AUD) | -129,463 | -230,114 |
Lease repayments (AUD) | -74,187 | -81,353 |
Dividends paid (AUD) | 0 | 0 |
Share buybacks (AUD) | 0 | 0 |
Net change in cash (AUD) | -423,666 | 2,317,223 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2025 | FY2026 | Note |
|---|---|---|---|
ROE (%) | n/m | n/m | Equity negative in FY2025; average equity near zero in FY2026 |
ROA on year-end assets (%) | -219.6 | -62.9 | Derived |
ROIC | n/m | n/m | Negative NOPAT; minimal invested capital |
Current ratio (x) | 0.47 | 1.57 | Derived |
Debt / equity (x) | n/m | 0.43 | Debt including leases |
Net debt / EBITDA (x) | n/m | n/m | Net cash in FY2026; negative EBITDA |
Interest coverage (x) | n/m | n/m | Negative EBIT |
Asset turnover on year-end assets (x) | 0.94 | 0.61 | Derived; FY2026 lower because of the cash build |
Receivable days | 37 | 52 | Trade receivables (net) / sales x 365, derived |
Inventory days | 196 | 61 | Inventory / hardware expense x 365, derived |
Payable days | 110 | 33 | Trade payables / hardware expense x 365, derived |
Cash conversion cycle (days) | 123 | 80 | Derived; excludes the benefit of customer prepayments (contract liabilities) |
Revenue by Region (AUD) and Revenue by Region (%)
| Region | FY2025 | FY2026 |
|---|---|---|
Australia revenue (AUD) | 956,740 | 2,041,828 |
International revenue (AUD) | 0 | 0 |
Australia share of revenue (%) | 100 | 100 |
State / Territory Details
| State / Territory | Customer and sites | Status (latest) |
|---|---|---|
Victoria | mecwacare: Trescowthick Centre (Prahran, 60 beds), Allenvale, Caldwell Manor, Park Hill (4 sites, 223 beds live at 30 June 2026); 22 facilities in total under the MSA | Rolling out; 10 sites targeted by end of 2026 |
New South Wales | Hardi Aged Care: Manly Vale (100 beds), Blacktown (48 beds plus 84-bed expansion), Wyoming (63 beds), Seven Hills (104 beds) live; 2 more sites by end of 2026; about 580 beds across 6 sites | Rolling out; nurse call being added |
New South Wales / ACT | Warrigal Care: 65 villas at a new retirement development; potential across 10 villages (~700 residents) | Implementation |
Western Australia | WACHS: Koolberrin Lodge, Narembeen (regional) | Ongoing subscription |
Share Price
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|
Share price at 30 June (AUD) | 0.315 | 0.18 | 0.04 | 0.012 | 0.014 | 0.01 | 0.02 |
Performance Window Details
| Performance window (to FY2026 close, A$0.02) | Approx. return | Caveat |
|---|---|---|
1 year | about +100% | FY2025 base is rounded to A$0.01; the true figure may differ materially |
3 years | about +67% | Base A$0.012 |
5 years | about −89% | Base A$0.18 |
Since IPO | about −90% | Base A$0.20 |
Valuation Multiples
| Multiple | At A$0.020 | At A$0.026 |
|---|---|---|
Market cap (AUD Mn) | 14.3 | 18.6 |
Enterprise value, mcap minus net cash of A$2.20M (AUD Mn) | 12.1 | 16.4 |
EV / Sales FY2026 (x) | 5.9 | 8.0 |
P/e Details
| P/E | n/m (loss) | n/m (loss) |
|---|---|---|
EV / EBITDA | n/m (negative) | n/m (negative) |
P/B (x) | 11.6 | 15.1 |
Capital Markets
| Item | Status |
|---|---|
Analyst consensus | Not available. Simply Wall St lists one covering analyst but no submitted estimates |
Dividend history | No dividends ever paid; none declared for FY2026 or FY2025 |
Dividend policy | No formal policy; losses and accumulated deficits preclude dividends |
Buyback authorisations | None; no current on-market buyback (FY2026 Note 22) |
Credit ratings (Moody's / S&P / Fitch) | Not rated |
Debt maturity profile | All interest-bearing debt (A$497,640 at a 15% fixed rate) matures within 1 year; repaid from the FY2026 R&D refund |
Options on issue | 154,249,999 (exercise prices A$0.02–A$0.05; expiries May 2027 – May 2029) |
Performance rights on issue | 88,700,000 |
Trading liquidity | Low; micro-cap with large daily percentage swings |
Analyst Conclusions
Management guidance
No quantitative revenue or earnings guidance has been issued. Operational targets:
-
10 mecwacare sites live by the end of calendar 2026.
-
Remaining two Hardi sites live by the end of calendar 2026.
-
Hardi nurse call rollout across four more sites.
-
Warrigal implementation.
-
Full mecwacare rollout by FY2028.
-
CEO incentive hurdles of 700, 2,000 and 4,000 contracted revenue-generating beds by June 2027, 2028 and 2029.
Consensus
Not available.
Bull case
-
The contracted backlog converts into visible revenue. Disclosed TCV of about A$12.3M (mecwacare ~A$8.8M, Hardi ~A$3.27M including the expansion, Warrigal ~A$0.2M) is about six times FY2026 sales revenue. If it is delivered on schedule through FY2028, it supports sustained growth and a rising recurring base.
-
Operating leverage is real. Revenue doubled in FY2026 while staff costs fell and the EBITDA loss narrowed. The positive June-quarter operating cash flow shows the model can cover costs during heavy deployment periods.
-
Nurse call broadens the opportunity. Hardi adopting nurse call across all six sites, and the explicit ability to replace legacy systems, can raise revenue per bed and make InteliCare an attractive bolt-on for consolidators in the sector.
Bear case
-
Lumpy hardware revenue hides a weak recurring base. SaaS was only A$196,799 in FY2026, about 5% of annual cash operating payments. Once deployment bursts end, cash flow could quickly turn negative again.
-
Dilution is relentless. Shares rose from 292M to 715M in two years, with about 243M more options and rights outstanding. Even successful execution may not lift per-share value much if more raisings follow.
-
Concentration and execution risk. One customer (mecwacare) dominates near-term receipts. Delays, leadership changes at the customer, or incumbent competition (Austco at about 46 times the revenue) could derail the growth path, as happened in FY2023–FY2024.
Catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing |
|---|---|
| September 2026 quarter 4C: whether positive operating cash flow continues | Late Oct 2026 |
| FY2026 Annual Report: top-20 holders and governance disclosures | Late Oct 2026 |
| AGM: incentive grants and board renewal | Nov 2026 |
| mecwacare: 10 sites live | Dec 2026 |
| Hardi: final 2 sites plus nurse call rollout | Dec 2026 |
| Receipt of the FY2026 R&D refund and repayment of the 15% facility | H2 CY2026 |
| H1 FY2027 results: revenue run-rate and SaaS growth | Feb 2027 |
| New contract signings (e.g. Bolton Clarke conversion, Warrigal expansion, new RAC operators) | Ongoing |
| Progress toward 700 contracted beds | Jun 2027 |
| Any further capital raising | Ongoing |
Analyst verdict
InteliCare reached a genuine operational turning point in FY2026. After six years of pilots and sub-A$1M revenue, it signed a contract with mecwacare worth about four times its annual revenue. Its anchor customers are expanding their deployments: Hardi added beds and nurse call, and Warrigal opened a new vertical. The company produced evidence that resonates with aged care operators facing labour shortages and a tougher regulatory regime: falls detection with no recorded errors during the evaluation, and overnight welfare checks reduced from 55 residents to 4. The balance sheet moved from net liabilities to net cash, and the June quarter delivered the first positive operating cash flow since listing.
The quality of that inflection is still unproven. Ninety per cent of revenue is one-off hardware. Recurring SaaS revenue is around A$0.2M a year, and the cost base is roughly A$4M. The positive quarter came from a burst of mecwacare deployments, not from recurring revenue covering costs. Shareholders have been diluted about 2.4 times in two years, and roughly a third more potential shares sit in options and rights, many priced near the current share price. Governance is thin, with a three-person board, related-party service payments and performance rights held by non-executive directors. InteliCare is also entering nurse call, a category where a well-capitalised ASX incumbent is consolidating the Australian market.
On balance, ICR is a high-risk, binary-leaning execution story. The investment case depends on whether bed-count milestones (700 by June 2027) and SaaS growth arrive before the next capital raising. If they do, the current valuation of about 6–8 times trailing EV/Sales may compress quickly as recurring revenue builds, and strategic interest from consolidators becomes plausible. If deployments slip, the company's history of revenue stalls and dilution suggests downside. Investors should treat the September and December 2026 quarterly cash flow reports, rather than contract announcements, as the decisive evidence.
APPENDIX: SOURCES
-
InteliCare FY2026 Appendix 4E and Financial Report (26 Aug 2026): https://bulletin.webull.com/qbd/announcement/20260827/499500959/2108c18c35cf181fa6aeae1074338111.pdf
-
InteliCare June 2026 Quarter Operations Update (29 Jul 2026): https://announcements.asx.com.au/asxpdf/20260729/pdf/0724wcp1rs4w7q.pdf
-
InteliCare Hardi contract expansion (28 Jul 2026): https://announcements.asx.com.au/asxpdf/20260728/pdf/0723js49w5flh7.pdf
-
InteliCare placement announcement (7 May 2026): https://announcements.asx.com.au/asxpdf/20260507/pdf/06zbqzwj4p0sf5.pdf
-
InteliCare Half-Year Report to 31 Dec 2025: https://announcements.asx.com.au/asxpdf/20260227/pdf/06wv1rl2q5p4sc.pdf
-
InteliCare December 2025 Quarter Update (30 Jan 2026): https://bulletin.webull.com/qbd/announcement/20260130/499500959/78821094b50f79e118b336d340098519.pdf
-
InteliCare NWR conference notice (25 Mar 2026): https://bulletin.webull.com/qbd/announcement/20260325/499500959/80940cebe1ce7f668520b6af899f74f4.pdf
-
InteliCare FY2025 Annual Report: https://announcements.asx.com.au/asxpdf/20250829/pdf/06njtxx6cn823z.pdf
-
InteliCare FY2024 Financial Report: https://announcements.asx.com.au/asxpdf/20240830/pdf/0679qj6dj2wbmf.pdf
-
InteliCare FY2023 Annual Report: https://announcements.asx.com.au/asxpdf/20231027/pdf/05wm26k3dvvsl3.pdf
-
InteliCare FY2022 Annual Report: https://www.asx.com.au/asxpdf/20221026/pdf/45gs8cyb8kq0yp.pdf
-
InteliCare Half-Year Report Dec 2022: https://www.asx.com.au/asxpdf/20230227/pdf/45m321nrprhmdr.pdf
-
InteliCare A$2.5M placement (29 Apr 2021): https://announcements.asx.com.au/asxpdf/20210429/pdf/44vzhc7c2zxm52.pdf
-
InvestSMART ICR announcements and summaries: https://www.investsmart.com.au/security/asx/icr/intelicare-holdings-limited/announcements
-
InvestSMART March 2026 quarter summary: https://www.investsmart.com.au/investment-tools/shares/asx-price-sensitive-announcements/asx-icr/2520242
-
InvestSMART June 2026 4C summary: https://www.investsmart.com.au/investment-tools/shares/asx-price-sensitive-announcements/asx-icr/2553980
-
Kalkine Media (June 2026 quarter coverage): https://kalkinemedia.com/au/news/announcements/intelicare-reports-first-positive-quarterly-cash-flow-of-384k-fueled-by-18m-revenue-in-q2-2026
-
Kalkine Media (operating cash flow coverage): https://kalkinemedia.com/au/news/announcements/intelicare-holdings-reports-384k-operating-cash-flow-in-june-quarter-amid-growing-mecwa-deployment
-
Kalkine Media (capital reconciliation, 23 Jul 2026): https://kalkinemedia.com/au/news/announcements/intelicare-finalizes-fy26-capital-reconciliation-files-overdue-appendix-3h-for-expired-options
-
The Weekly Source (Aug 2026): https://www.theweeklysource.com.au/intelicare-reaches-commercial-inflexion-point/
-
The Weekly Source (Pilbrow resignation, Aug 2025): https://www.theweeklysource.com.au/daniel-pilbrow-resigns-as-ceo-of-ai-care-platform-intelicare-for-a-new-job/
-
The Weekly Source (IPO, May 2020): https://theweeklysource.com.au/aged-care-tech-platform-intelicare-nearly-double-ipo-price-on-asx-debut?amp=1
-
StockWireX (mecwacare deal, Mar 2026): https://stockwirex.com/asx-stock-news/biotech-health/icr-intelicare-mecwacare-8-8m-agreement-march-2026/
-
TipRanks (Hardi third and fourth facilities): https://www.tipranks.com/news/company-announcements/intelicare-expands-deployment-with-hardi-aged-care-anticipates-saas-revenue-growth
-
Market Index ICR profile: https://www.marketindex.com.au/asx/icr
-
Morningstar ICR profile: https://www.morningstar.com.au/investments/security/asx/ICR
-
Simply Wall St ICR ownership: https://simplywall.st/stocks/au/healthcare/asx-icr/intelicare-holdings-shares/ownership
-
ROIC.ai ICR summary: https://www.roic.ai/quote/ICR.AX/classic
-
Business News (IPO, 25 May 2020): https://www.businessnews.com.au/Company/31827/News
-
Startup News (IPO, May 2020): https://startupnews.com.au/news/intelicare-lists-successfully-on-the-asx/
-
Stockhead IPO Watch (2020): https://stockhead.com.au/?p=53817
-
IT Brief (Pilbrow appointment, Jul 2022): https://itbrief.com.au/story/intelicare-appoints-daniel-pilbrow-as-ceo
-
Stockhead (March 2022 quarter): https://stockhead.com.au/?p=207650
-
Strawman ICR notes: https://strawman.com/reports/ICR/all
-
Austco Healthcare FY2026 results (FilingReader): https://filingreader.com/news-wire/sydney/2026-08-27/austco-healthcare-posts-record-fy26-revenue-and-profit-growth
-
Austco Healthcare FY2026 results (SmallCaps): https://smallcaps.com.au/article/austco-healthcare-posts-record-fy26-revenue-as-recurring-income-builds
-
Austco Healthcare H1 FY2026 (Strawman): https://strawman.com/reports/AHC/Jimmy
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Prior roles | FY2026 total remuneration (AUD) |
|---|---|---|---|---|
Angus Cameron | Chief Executive Officer | Since 16 Mar 2026 | 30+ years across aged care, health and technology in Australia, Asia-Pacific and the US; senior roles at Philips Healthcare (digital transformation, smart hospital strategy, health system partnerships) | 164,222 (part year: salary 94,027; super 11,283; equity 58,912) |
Mike Tappenden | Chief Technology Officer; co-founder | Service agreement since 20 Dec 2019 | Co-founder; relevant interest in Forward Logic Pty Ltd | 310,677 (salary 232,875; super 27,945; equity 49,857) |
Neil Hackett | Company Secretary | Board member until 15 Sep 2022; company secretary since then | — | — |
Daniel Pilbrow (former) | CEO | 18 Jul 2022 – 10 Oct 2025 | Silver Chain Group (Executive Director NSW, national M&A); also described as former Chief Strategy Officer at Opal HealthCare and with AMP Capital's social care division; trained physiotherapist | 184,871 (part year) |
“—” = not publicly disclosed.
Board of Directors
| Name | Role | Appointed | Background | Shares | Perf. rights | Options | FY2026 total (AUD) |
|---|---|---|---|---|---|---|---|
Dr Neale Fong | Non-Executive Chairman | 21 Apr 2022 (initially Executive Chair) | Medical practitioner, 35+ years in health leadership; CEO and Executive Director of Bethesda Health Care; former Director General of WA Health; former CEO of St John of God Subiaco; former NED of Little Green Pharma (to June 2026) | 0 | 18,500,000 | 3,000,000 | 165,227 |
Greg Leach | Non-Executive Director; co-founder | Founder | 30+ years in ICT; co-founder and former CTO of Empired Ltd; co-founder of Frontline Services (now Forward Logic), BigRedSky; CEO of Blockhead Technologies; B.Bus (Information Processing) | 46,046,019 | 12,400,000 | 4,666,667 | 90,686 |
Tim Chapman | Non-Executive Director (Interim Executive Director Oct 2025 – Mar 2026) | 25 Sep 2024 | 25+ years in corporate finance (IPOs, placements, M&A) focused on small-cap healthcare; founder of Clarity Capital Advisors; Chairman of HeraMED (ASX: HMD) | 1,335,181 | 12,000,000 | 13,253,954 | 90,339 |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
25 Sep 2024 | Cam Ansell leaves the board; Tim Chapman joins | Board renewal toward capital markets expertise |
Aug 2025 | Pilbrow resignation announced | Left for a senior role at a large aged care provider |
10 Oct 2025 | Pilbrow departs; Chapman becomes Interim Executive Director with Tappenden | Leadership gap during the mecwacare pilot |
16 Mar 2026 | Angus Cameron appointed CEO | Coincided with the mecwacare MSA |
Major Shareholders
| Holder | Shares | Stake | Basis / date | Source |
|---|---|---|---|---|
Greg Leach (director and founder) | 46,046,019 | ~6.44% | Of 714.75M shares, 30 Jun 2026 | FY2026 Remuneration Report |
Christopher Weed | 38,300,000 acquired | ~5–6% (derived; share count at time of purchase not confirmed) | On-market purchase about A$841k, 14 Nov 2025 | Simply Wall St |
Citicorp Nominees Pty Ltd | 30,936,145 | 6.35% | On ~487M shares (FY2025 annual report top 20) | Market Index |
Carl Charalambous (and Chara Brothers) | 27,727,374 at the Aug 2024 notice; further purchases late 2024 | 5.70% at notice | Substantial holder notice, 30 Aug 2024 | Market Index; Simply Wall St |
Ratdog Pty Ltd | 20,053,839 | 4.12% | FY2025 top 20 | Market Index |
Altor Capital Management | 20,422,099 | 9.72% at the time | Notice dated 23 Oct 2023 (since heavily diluted) | Market Index |
Tim Chapman (director) | 1,335,181 | ~0.19% | 30 Jun 2026 | FY2026 Remuneration Report |
KMP total direct shareholding | 47,381,200 | ~6.63% | 30 Jun 2026 | FY2026 Remuneration Report |
Competitive Landscape
Key Competitors
| # | Competitor | Category overlap | Listing | Positioning vs InteliCare |
|---|---|---|---|---|
| 1 | Austco Healthcare | Nurse call and clinical communications (core overlap since InteliCare's nurse call launch) | ASX: AHC | Incumbent with scale: FY2026 revenue A$94.2M, 5,000+ facilities in 60+ countries |
| 2 | Ascom | Nurse call and clinical workflow, aged care and hospitals | SIX: ASCN | — |
| 3 | Baxter (Hillrom / Voalte) | Nurse call and care communications | NYSE: BAX | — |
| 4 | Tunstall | Telecare, nurse call, community alarms | Private | Large legacy telecare provider; figures not disclosed |
| 5 | SafelyYou | AI video-based falls detection in senior living | Private (US) | Camera-based approach versus InteliCare's sensor-based approach |
| 6 | Vayyar | Radar-based contactless falls detection | Private (Israel) | Privacy-preserving sensing competitor |
| 7 | Kepler Vision Technologies | Computer-vision night monitoring and falls | Private (Netherlands) | Overnight monitoring competitor |
| 8 | Nobi | Smart lamp with falls detection | Private (Belgium) | Ambient device competitor |
| 9 | Electronic Caregiver | Remote monitoring and virtual care | Private (US) | Home monitoring overlap |
| 10 | Alcidion | Clinical informatics and smart hospital software | ASX: ALC | — |
| 11 | Aged care management system vendors (e.g. AlayaCare and others) | Care management and workflow | Mostly private | Integration partners or substitutes for dashboard features |
Peer Comparison FY2026
| Metric (FY2026, AUD) | InteliCare (ICR) | Austco Healthcare (AHC) |
|---|---|---|
Revenue | A$2.04M | A$94.2M |
Revenue growth | +113.4% | +15.8% |
EBITDA margin | −90.4% | ~15.8% (EBITDA A$14.9M) |
NPAT | −A$2.10M | A$9.0M |
R&D intensity | Not disclosed (development expense 14.6% of revenue) | — |
Cash | A$2.73M | A$16.3M (no material borrowings) |



